Xiaojin Shi

3.0k total citations · 1 hit paper
91 papers, 2.2k citations indexed

About

Xiaojin Shi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaojin Shi has authored 91 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 26 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaojin Shi's work include Lung Cancer Treatments and Mutations (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Xiaojin Shi is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Xiaojin Shi collaborates with scholars based in China, United States and Japan. Xiaojin Shi's co-authors include Mingkang Zhong, Zheng Jiao, Tony Mok, Zhongdong Li, Qunyi Li, Liyuan Li, Zhao Wang, Yun Shi, Myung‐Ju Ahn and Santiago Ponce and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Xiaojin Shi

82 papers receiving 2.2k citations

Hit Papers

Durvalumab With or Without Tremelimumab in Combination Wi... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
    2022 238 citations Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology profile →

Peers

Xiaojin Shi
Jürgen Venitz United States
Stefano Fogli Italy
Li Yu China
Scott J. Weir United States
Shigemi Matsumoto Japan
Alexander Staab Germany
Bo Jiang China
Stacy S. Shord United States
Nan Song China
Karol Kajo Slovakia
Jürgen Venitz United States
Xiaojin Shi
Citations per year, relative to Xiaojin Shi Xiaojin Shi (= 1×) peers Jürgen Venitz

Countries citing papers authored by Xiaojin Shi

Since Specialization
Citations

This map shows the geographic impact of Xiaojin Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojin Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojin Shi more than expected).

Fields of papers citing papers by Xiaojin Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojin Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojin Shi. The network helps show where Xiaojin Shi may publish in the future.

Co-authorship network of co-authors of Xiaojin Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojin Shi. A scholar is included among the top collaborators of Xiaojin Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojin Shi. Xiaojin Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Yan, et al.. (2025). Axis-Squeeze and Multirouting Scale-Adaptive Fusion Network for Remote Sensing Images Object Detection. IEEE Transactions on Geoscience and Remote Sensing. 63. 1–15.
2.
Chen, Lu, Xinhai Wang, Xiang Mao, et al.. (2025). VSIG4 Promotes Tumour‐Associated Macrophage M2 Polarization and Immune Escape in Colorectal Cancer via Fatty Acid Oxidation Pathway. Clinical and Translational Medicine. 15(5). e70340–e70340. 7 indexed citations
3.
4.
Liu, Ju, et al.. (2024). Long–cycling lithium–sulfur battery enabled by acrylic modified epoxy soybean oil UV–curing binder. Journal of Electroanalytical Chemistry. 968. 118502–118502. 2 indexed citations
5.
6.
Xu, Chang‐An, et al.. (2024). Silicone and nano-diamond modified graphene oxide anticorrosive coating. Surface and Coatings Technology. 479. 130584–130584. 8 indexed citations
7.
Chen, Lu, Huanying Shi, Yongjun Zhu, et al.. (2024). Metabolism score and machine learning models for the prediction of esophageal squamous cell carcinoma progression. Cancer Science. 115(9). 3127–3142. 1 indexed citations
8.
9.
Zhang, Yanan, et al.. (2024). The Health Effects of Dietary Nitrate on Sarcopenia Development: Prospective Evidence from the UK Biobank. Foods. 14(1). 43–43. 1 indexed citations
10.
Xu, Tiantian, et al.. (2024). Multifunctional coatings fabricated from Chinese hemp–derived superhydrophobic micro–nanocellulose. International Journal of Biological Macromolecules. 263(Pt 2). 130430–130430. 3 indexed citations
11.
Shi, Xiaojin, et al.. (2023). The Association between Sugar-Sweetened Beverages and Male Pattern Hair Loss in Young Men. Nutrients. 15(1). 214–214. 11 indexed citations
12.
Garon, Edward B., Byoung Chul Cho, Alexander Luft, et al.. (2023). Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 186. 107422–107422. 4 indexed citations
13.
Wang, Yan, Tianxiao Wang, Wenxin Zhang, et al.. (2023). STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy. Journal of Chemotherapy. 36(1). 61–71. 1 indexed citations
14.
Ye, Chuchu, Yuanping Wang, Dong Li, et al.. (2022). Parental Seasonal Influenza Vaccine Hesitancy and Associated Factors in Shanghai, China, during the COVID-19 Pandemic: A Cross-Sectional Study. Vaccines. 10(12). 2109–2109. 16 indexed citations
15.
Johnson, Melissa L., Byoung Chul Cho, Alexander Luft, et al.. (2022). Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology. 41(6). 1213–1227. 238 indexed citations breakdown →
16.
Zhang, Liudi, Yingfeng Zhu, Haixia Cheng, et al.. (2018). The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma. Molecular Cancer Therapeutics. 18(1). 173–184. 12 indexed citations
17.
Asahina, Hajime, Hiroshi Nokihara, Noboru Yamamoto, et al.. (2012). Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Investigational New Drugs. 31(3). 677–684. 33 indexed citations
18.
Shi, Xiaojin. (2007). Simultaneous separation and determination of zonisamide,phenytoin carbamazepine and carbamazepine 10,11-epoxide in human plasma using isocratic reversed-phase HPLC. 1 indexed citations
19.
Li, Zhongdong, Xiaojin Shi, Bei Wang, et al.. (2007). Determination of Ezetimibe and Total Ezetimibe in Human Plasma and Its Pharmacokinetics. Zhōnghuá yàoxué zázhì. 42(7). 531–535. 1 indexed citations
20.
Jiao, Zheng, et al.. (2006). Study on Bioequivalence of Risperidone Tablets. Zhōnghuá yàoxué zázhì. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jürgen Venitz Breakdown of academic impact, for papers by Stefano Fogli Breakdown of academic impact, for papers by Li Yu Breakdown of academic impact, for papers by Scott J. Weir Breakdown of academic impact, for papers by Shigemi Matsumoto Breakdown of academic impact, for papers by Alexander Staab Breakdown of academic impact, for papers by Bo Jiang Breakdown of academic impact, for papers by Stacy S. Shord Breakdown of academic impact, for papers by Nan Song Breakdown of academic impact, for papers by Karol Kajo
Rankless by CCL
2026